| Autor: |
Mosenzon, Ofri, Blicher, Thalia Marie, Rosenlund, Signe, Eriksson, Jan W, Heller, Simon, Hels, Ole Holm, Pratley, Richard, Sathyapalan, Thozhukat, Desouza, Cyrus, Abramof, R, Alpenidze, D, Aronoff, S, Astamirova, K, Barker, B, Bedel, G, Belousova, L, Benson, M, Beshay, I, Biggs, W, Blaze, K, Bogdanski, P, Busch, R, Chaidarun, S, Chandran, S, Chang, A, Chilka, S, Cleland, A, Connery, L, Cornett, G, Delgado, B, Desouza, C, Donner, T, Eliasson, K, Eriksson, J, Folkerth, S, Forshaw, K, Frandsen, H A, Frolova, E, Gandy, W, Gatipon, G, Golovach, A, Gonzalez-Orozco, L, Gumprecht, J, Haddad, E, Hansen, T K, Hart, T, Hasan, S, Hella, B, Heller, S, Hellgren, M, Hewitt, M, Hietaniemi, S, Hitz, M, Houser, P, Huntley, R, Jackson, R, Jakobsen, P E, Kapoor, A, Kargina, L, Kazakova, E, Khan, K, Klein, E, Knoble, H, Krasnopeeva (Kabachkova), N, Krzeminski, A, Kunitsyna, M, Lawhead, J, Levin, K, Levin, P, Lewy-Alterbaum, L, Lindmark, S, Lindsay, R, Luts, A, Lysenko, T, Madsbad, S, Maxwell, T, Mbogua, C, Mcknight, J, Metsärinne, K, Milovanova, T, Morawski, E, Mosenzon, O, Nabriski, D, Nguyen, H, Nicol, P, Nieminen, S, Nikkola, A, Norwood, P, O'Donnell, P, Odugbesan, A, Parker, J, Pergaeva, Y, Peskov, A, Plevin, S, Pouzar, J, Pratley, R, Reed, J, Rossing, P, Sathyapalan, T, Sergeeva-Kondrachenko, M, Shaikh, Z, Shamkhalova, M, Shehadeh, N, Shlesinger, Y, Silver, R, Snyder, B, Soufer, J, Strand, J, Sulosaari, S, Tirosh, A, Traylor, H, Uhlenius, N, Vagapova, G, Yanovskaya, M, Zarutskaya, L, Zhdanova, E |
| Zdroj: |
The Lancet Diabetes & Endocrinology; July 2019, Vol. 7 Issue: 7 p515-527, 13p |
| Abstrakt: |
Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We aimed to investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
